Advances in pemphigus therapy.
The pemphigus variants represent a group of potentially life-threatening autoimmune mucocutaneous blistering diseases. Though systemic corticosteroids have dramatically reduced the rate of disease mortality, current therapeutic options are limited by their toxicity profiles. Advancements in our understanding of the molecular mechanisms involved in the pathogenesis of pemphigus have translated into the development of novel therapies. However, few treatments have been subject to randomized controlled trials to firmly establish therapeutic efficacy. Herein, we focus on the new and emerging therapies in the management of pemphigus.
Prajapati
V
V
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Mydlarski
P R
PR
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D007164:Immunosorbents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010392:Pemphigus / Q000628:therapy*; D017893:Photopheresis; D010956:Plasmapheresis
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D007164:Immunosorbents; D007166:Immunosuppressive Agents